Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Anti-CD20-based therapy of B cell lymphoma: state of the art

Leukemia volume 16, pages 2004–2015 (2002)Cite this article

Abstract

Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotope-labeled murine anti-CD20 MAbs are currently employed with encouraging results as monotherapy or in combination with conventional chemotherapy and in consolidation of remission after treatments with curative intent (ie after/ in combination with high-dose chemotherapy and hematopoietic stem cell rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the treatment of B cell NHL and related malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975 256: 495–497

    CAS  PubMed  Google Scholar 

  2. Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF . Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Res 1980 40: 3147–3154

    CAS  PubMed  Google Scholar 

  3. Miller RA, Maloney DG, Warnke R, Levy R . Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody N Engl J Med 1982 306: 517–522

    CAS  PubMed  Google Scholar 

  4. Dickman S . Cancer therapy – antibodies stage a comeback in cancer treatment Science 1998 280: 1196–1197

    CAS  PubMed  Google Scholar 

  5. Maloney D . Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches Curr Opin Hematol 1999 6: 222–228

    CAS  PubMed  Google Scholar 

  6. Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, Ritter MA . Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms Cancer Res 1986 46: 6489–6493

    CAS  PubMed  Google Scholar 

  7. Stashenko P, Nadler LM, Hardy R, Schlossman SF . Characterization of a human B lymphocyte-specific antigen J Immunol 1980 125: 1678–1685

    CAS  PubMed  Google Scholar 

  8. Anderson K, Bates M, Slaughenhoup B, Pinkus GS, Schlossman SF, Nadler LM . Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentation Blood 1984 63: 1424–1433

    CAS  PubMed  Google Scholar 

  9. O'Keefe TL, Williams GT, Davies SL, Neuberger MS . Mice carrying a CD20 gene disruption Immunogenetics 1998 48: 125–132

    CAS  PubMed  Google Scholar 

  10. Bubien JK, Zhou L-J, Bell PD, Frizzell RA, Tedder TF . Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B-lymphocytes J Cell Biol 1993 121: 1121–1132

    CAS  PubMed  Google Scholar 

  11. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA . Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains EMBO J 1988 7: 711–717

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Tedder TF, Engel P . CD20: a regulator of cell cycle progression of B-lymphocytes Immunol Today 1994 15: 450–454

    CAS  PubMed  Google Scholar 

  13. Deans JP, Robbins SM, Polyak MJ, Savage JA . Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment J Biol Chem 1998 273: 344–348

    CAS  PubMed  Google Scholar 

  14. Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-Ud-Din . Signalling through sphingolipid microdomains of the plasma membrane: the concept of a signalling platform Glucoconj 2000 17: 191–197

    CAS  Google Scholar 

  15. Reff M, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 1994 83: 435–445

    CAS  PubMed  Google Scholar 

  16. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, Thomas ED . Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas Blood 1987 69: 584–591

    CAS  PubMed  Google Scholar 

  17. McLaughlin P . Rituximab: perspective on single agent experience, and future directions in combination trials Crit Rev Oncol/Hematol 2001 40: 3–16

    CAS  Google Scholar 

  18. Cragg MS, French RR, Glennie MJ . Signaling antibodies in cancer therapy Curr Opin Immunol 1999 11: 541–547

    CAS  PubMed  Google Scholar 

  19. Popoff IJ, Savage JA, Blake J, Johnson P, Deans JP . The association between CD20 and Src-family tyrosine kinases requires an additional factor Mol Immunol 1998 35: 207–214

    CAS  PubMed  Google Scholar 

  20. Grillo-Lopez AJ . Rituximab: an insider's historical perspective Semin Oncol 2000 27: 9–16

    CAS  PubMed  Google Scholar 

  21. Demidem A, Alas S, Lam T, Hariharan K, Hanna N, Bonavida B . Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug-resistant human B cell lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins FASEB J 1995 9: A206

    Google Scholar 

  22. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B . Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Biother Radiopharm 1997 12: 177–185

    CAS  PubMed  Google Scholar 

  23. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M . Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 2000 95: 3900–3908

    CAS  PubMed  Google Scholar 

  24. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M . CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 2001 98: 3383–3389

    CAS  PubMed  Google Scholar 

  25. Weng WK, Levy R . expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 2001 98: 1352–1357

    CAS  PubMed  Google Scholar 

  26. Maloney D, Liles T, Czerwinski D, Waldichuck C, Rosenberg J, Grillo-Lopez A, Levy R . Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8)in patients with recurrent B cell lymphoma Blood 1994 84: 2457–2466

    CAS  PubMed  Google Scholar 

  27. Maloney D, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R . IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 1997 15: 3266–3274

    CAS  PubMed  Google Scholar 

  28. Maloney D, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R . IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 1997 90: 2188–2195

    CAS  PubMed  Google Scholar 

  29. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R . Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab J Clin Oncol 1999 17: 1851–1857

    CAS  PubMed  Google Scholar 

  30. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V . Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 1999 10: 655–661

    CAS  PubMed  Google Scholar 

  31. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825–2833

    CAS  PubMed  Google Scholar 

  32. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P . Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation Blood 2001 97: 101–106

    CAS  PubMed  Google Scholar 

  33. Thomas D, O'Brien S, Cortes J, Faderl S, Fayad L, Garcia-Manero G, Wierda W, Verstovsek S, Kornblau S, Pierce S, Kantarjian H, Keating M . Treatment of splenic lymphoma with villous lymphocytes and marginal zone lymphomas with single agent Rituximab Blood 2001 98 (Suppl. 1): 134a (Abstr. 563)

    Google Scholar 

  34. Conconi A, Thieblemont C, Martinelli G, Ferreri A, Devizzi L, Peccatori F, Ponzoni M, Filipazzi V, Dietrich P, Gianni M, Cavalli F, Zucca E . Activity of Rituximab in extranodal marginal zone lymphomas Blood 2001 98 (Suppl. 1): 807a (Abstr 3354)

    Google Scholar 

  35. Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foa R . Efficacy of Mabthera (anti-CD20 Ab) in patients with relapsed/progressed hairy cell leukemia Haematologica 2001 86: 1046–1050

    CAS  PubMed  Google Scholar 

  36. Treon S, Agus T, Link B, Rodrigues G, Molina A, Lacy M, Fisher D, Emmanouilides C, Richards A, Clark B, Lucas M, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson K, Byrd J . CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia J Immunother 2001 24: 272–279

    CAS  PubMed  Google Scholar 

  37. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F . Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 1998 92: 1927–1939

    CAS  PubMed  Google Scholar 

  38. Foran JM, Rohatiner AZ, Cunningham D, Popescu R, Solal-Celigny P, Ghielmini M, Coiffier B, Johnson P, Gisselbrecht C, Reyes F, Radford J, Bessell E, Souleau B, Benzohra A, Lister TA . European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 2000 18: 317–324

    CAS  PubMed  Google Scholar 

  39. Ghielmini M, Schmitz SF, Burki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F, Cerny T . The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK) Ann Oncol 2000 11 (Suppl. 1): 123–126

    Google Scholar 

  40. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D . Levels of expression of CD19 and CD20 in chronic B cell leukemias J Clin Pathol 1998 51: 364–369

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Winkler U, Jensen M, Manzke O, Schultz H, Diehl V, Engert A . Cytokine release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8) Blood 1999 94: 2217–2224

    CAS  PubMed  Google Scholar 

  42. Keating MJ, O'Brien S, Albitar M . Emerging information on the use of rituximab in chronic lymphocytic leukemia Semin Oncol 2002 29 (1 Suppl. 2): 70–74

    Google Scholar 

  43. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ . Rituximab dose-escalation trial in chronic lymphocytic leukemia J Clin Oncol 2001 19: 2165–2170

    CAS  PubMed  Google Scholar 

  44. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW . Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity J Clin Oncol 2001 19: 2153–2164

    CAS  PubMed  Google Scholar 

  45. Hainsworth J, litchy S, Burris H, Greco F . Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma and chronic lymphocytic leukemia Blood 2001 98 (Suppl. 1): 363a (Abstr. 1530)

    Google Scholar 

  46. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B . German Chronic Lymphocytic Leukemia Study Group: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia Blood 2001 98: 1326–1331

    CAS  PubMed  Google Scholar 

  47. Manshouri T, Saffer H, Keating M, Albitar M . Clinical relevance of circulating CD20 in patients with chronic lymphocytic leukemia Blood 2000 96 (Suppl. 1): 369a (Abstr. 1595)

    Google Scholar 

  48. Garcia Manero G, O'Brien S, Cortes J, Faderl S, Giles F, Albitar M, Lerner S, Kantarjian H, Keating M . Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia Blood 2001 98 (Suppl. 1): 633a (Abstr. 2650)

    Google Scholar 

  49. Czuczman M, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268–276

    CAS  PubMed  Google Scholar 

  50. Rambaldi A, Carlotti E, Baccarani M, Barbui T, Dastoli G, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ruplo M, Tura S, Zaja F, Zinzani P, Reato G, Foa R . Monitoring of minimal residual disease after CHOP and Rituximab in previously untreated follicular lymphoma patients Blood 2001 98 (Suppl. 1): 603a (Abstr. 2528)

    Google Scholar 

  51. Hiddemann W, Forstpointner R, Fiedler F, Gramatzki M, Dorken B, Illiger H, Kneba M, Pfreundschuh M, Parsold R, Parwaresch R, Dreyling M, Unterhalt M for the GLSG. The addition of Rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular and mantle cell lymphomas. Results of a prospective randomized comparison of the German Low Grade Study Group Blood 2001 98 (Suppl. 1): 844a (Abstr. 3507)

    Google Scholar 

  52. Gregory S, Venugopal P, Adler S, O'Brien T, O'Donnell K, Yunus F . Safety and efficacy of fludarabine and mitoxantrone with Rituximab consolidation in untreated advanced low grade non Hodgkin's lymphoma Blood 2001 98 (Suppl. 1): 605a (Abstr. 2534)

    Google Scholar 

  53. Czuczman M, Fallon A, Mohr A, Stewart C, Klippenstein D, Loud P, Lamonica D, Bernstein Z, McCarthy P, Skipper M, Brown K, Miller K, Wentling D, Rock M, Benyunes M, Grillo-Lopez A, Bernstein S . Phase II study of Rituximab plus fludarabine in patients with low grade lymphoma: final report Blood 2001 98 (Suppl. 1): 601a (Abstr. 2518)

    Google Scholar 

  54. Nabhan C, Tallman MS, Riley MB, Fitzpatrick J, Gordon LI, Gartenhaus R, Kuzel T, Siegel R, Rosen ST . Phase I study of rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukemia Blood 2001 98 (Suppl. 1): 365a (Abstr. 1536)

    Google Scholar 

  55. Faderl S, Thomas DA, O'Brien S, Giles F, Koller CA, Beran M, Williams M, Garcia-Manero G, Kantarjian HM, Keating MJ . An exploratory study of the combination of monoclonal antibodies CAMPATH-1H and rituximab in the treatment of CD52- and CD20-positive chronic lymphoid disorders Blood 2001 98 (Suppl. 1): 365a (Abstr. 1537)

    Google Scholar 

  56. Leonard JP, Coleman M, Matthews JC, Fiore JM, Dosik A, Kapushoc H, Kin E, Cesano A, Wegener WA, Goldenberg DM . Combination monoclonal antibody therapy for lymphoma: treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated Blood 2001 98 (Suppl. 1): 844a (Abstr. 3506)

    Google Scholar 

  57. Hariharan K, Anderson D, Leigh B, Berquist LG, Murphy T, Leonard JE, Braslawsky GR, Hanna N . Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (RituxanΛ) in B-cell lymphoma Blood 2001 98 (Suppl. 1): 608a (Abstr. 2549)

    Google Scholar 

  58. Kimby E, Geisler C, Hagberg H, Holte H, Lehtinen T, Sundström C on behalf of the Nordic Lymphoma Group. Rituximab as single agent and in combination with interferon-alpha-2a as treatment of untreated and first relapse follicular or other low grade lymphomas: a randomized phase II study Blood 2000 96 (Suppl 1): 577a (Abstr. 2479)

    Google Scholar 

  59. Hsu FL, Komarovskaya M, Song L, Doyon AG . A clinical trial of sequential dendritic cell and protein/adjuvant idiotype vaccines in patients with follicular lymphomas Blood 2001 98 (Suppl. 1): 466a (Abstr. 1950)

    Google Scholar 

  60. Fisher R, Gaynor E, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens in advanced non-Hodgkin's lymphoma N Engl J Med 1995 328: 1002–1006

    Google Scholar 

  61. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel L, Fisher R . Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 2001 19: 389–397

    CAS  PubMed  Google Scholar 

  62. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Gisselbrecht . CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma N Engl J Med 2002 346: 235–242

    CAS  PubMed  Google Scholar 

  63. Gutierrez ME, Grossbard ML, Little RF, Elwood PC, Pearson D, Jaffe E, Chabner BA, Wilson WH . Dose-adjusted EPOCH chemotherapy (CT) and rituximab (EPOCH-R): an effective regimen in poor prognosis aggressive B-cell non-Hodgkin's lymphoma (NHL) Proc Am Soc Clin Oncol 2000 19: 26a (Abstr. 95)

    Google Scholar 

  64. Kewalrami T, Zelenetz A, Bertino J, Donnelly G, Hedrick E, Noy A, O'Connor O, Portlock C, Straus D, Yahalom Y, Gencarelli A, Remy D, Qin J, Nimer S, Moskowitz C . Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy Blood 2001 98 (Suppl. 1): 346a (Abstr. 1459)

    Google Scholar 

  65. Thomas D, Cortes J, Giles F, Faderl S, O'Brien S, Garcia-Manero G, Pierce S, Keating M, Cabanillas F, Kantarjian H . Rituximab and Hyper-CVAD for adult Burkitt's or Burkitt's-like leukemia or lymphoma Blood 2001 98 (Suppl. 1): 804a (Abstr. 3342)

    Google Scholar 

  66. Tirelli U, Sparano JA, Hopkins U, Spina M, Vaccher E . Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphoma (NHL) Proc Am Soc Clin Oncol 2000 19: 44a (Abstr. 170)

    Google Scholar 

  67. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R . Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 1998 16: 3803–3809

    CAS  PubMed  Google Scholar 

  68. Romaguera J, Cabanillas F, Dang N, Goy A, Hagemeister F, Fayad L, Mclaughlin P, Pro B, Rodriguez M, Semaniego F, Sarris A, Younes A, Medeiros J . Mantle cell lymphoma-High rates of complete remission and prolonged failure-free survival with Rituxan-HyperCVAD without stem cell transplant Blood 2001 98 (Suppl. 1): 726a (Abstr. 3030)

    Google Scholar 

  69. Buckstein R, Imrie K, Spaner D, Potichnyj A, Robinson JB, Nanji S, Pennel N, Reis M, Pinkerton P, Dube I, Hewitt K, Berinstein NL . Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol 1999 26 (Suppl. 14): 115–122

    Google Scholar 

  70. Flinn IW, O'Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S, Marcellus D, Borowitz M, Jones R, Ambinder RF . Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma Biol Blood Marrow Transplant 2000 6: 628–632

    CAS  PubMed  Google Scholar 

  71. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G, Gianni AM . Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion Blood 2000 96: 864–869

    CAS  PubMed  Google Scholar 

  72. Voso MT, Pantel G, Weis M, Schmidt P, Martin S, Moos M, Ho AD, Haas R, Hohaus S . In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma Br J Haematol 2000 109: 729–735

    CAS  PubMed  Google Scholar 

  73. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Boccadoro M, Pileri A, Gianni AM, Tarella C . Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin7rsquo;s lymphoma Leukemia 2001 15: 1941–1949

    CAS  PubMed  Google Scholar 

  74. Flinn IW, Jones R, Goodrich A, Carter-Brookins D, Moss T, Loper C . Noga S, Berdeja J, Ambinder R. Rituximab during autologous stem cell transplantation for lymphoma produces lymphoma free grafts in most patients by PCR and clonogenic assays Blood 2001 98 (Suppl. 1): 676a (Abstr. 2832)

    Google Scholar 

  75. Lazzarino M, Arcaini L, Bernasconi P, Alessandrino EP, Gargantini L, Cairoli R, Orlandi E, Astori C, Brusamolino E, Pagnucco G, Colombo AA, Calatroni S, Iacona I, Regazzi MB, Morra E . A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma Br J Haematol 2002 116: 229–235

    CAS  PubMed  Google Scholar 

  76. Berinstein NL, Buckstein R, Imrie K, Spaner D, Mangel J, Tompkins K, Pennell N, Reis M, Pavlin P, Lima A, Couvadia A, Robinson J, Richardson P . Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma Bone Marrow Transplant 2002 29 (Suppl. 1): S14–S17

    Google Scholar 

  77. Gianni AM, Cortelazzo S, Magni M, Martelli M for the Michelangelo Cooperative. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma Bone Marrow Transplant 2002 29 (Suppl. 1): S10–S13

    Google Scholar 

  78. Gisselbrecht C . In vivo purging and relapse prevention following ASCT Bone Marrow Transplant 2002 29 (Suppl 1): S5–S9

    Google Scholar 

  79. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki-Sofianatou K . Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases Leuk Res 2002 26: 597–600

    CAS  PubMed  Google Scholar 

  80. Horwitz S, Negrin R, Stockerl-Goldstein K, Johnston L, Shizuru J, Stuart M, Breslin S, Blume K, Horning S . Phase II trial of Rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory non Hodgkin's lymphomas Blood 2001 98 (Suppl. 1): 862a (Abstr. 3578)

    Google Scholar 

  81. Buckstein R, Imrie K, Spaner D, Mangel J, Tompkins K, Crump M, Coovadia A, Reis M, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Bourdeau A, Gitelson E, Berinstein NL . Autologous stem cell transplants combined with Rituximab for relapsed follicular lymphoma achieve prolonged clinical and molecular remissions Blood 2001 98 (Suppl. 1): 680a (Abstr. 2846)

    Google Scholar 

  82. Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL . Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma Semin Oncol 2002 29 (Suppl. 2): 56–69

    Google Scholar 

  83. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V . Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients Ann Oncol 2000 11 (Suppl. 1): 113–116

    Google Scholar 

  84. Faye A, Van Den Abeele T, Peuchmaur M, Mathieu-Boue A, Vilmer E . Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders Lancet 1998 352: 1285

    CAS  PubMed  Google Scholar 

  85. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM . CD20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab Am J Hematol 2000 65: 171–173

    CAS  PubMed  Google Scholar 

  86. Kentos A, Knoop C, Wissing M, Robin V, Remmelinx M, Garbar C, Goldman S, El Housni H, Feremans W, Estenne M . Anti-CD20 monoclonal antibody as first-line treatment of post-transplant B-lymphoproliferative disorders in solid organ transplant recipients. A report of eight cases observed in a single center Blood 2001 98 (Suppl. 1): 344a (Abstr. 1451)

    Google Scholar 

  87. Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, Rooney CM, Heslop HE . CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation Blood 2000 95: 1502–1505

    CAS  PubMed  Google Scholar 

  88. Illidge TM, Cragg MS, McBride HM, French RR, Glennie MJ . Radioimmunotherapy of B-cell lymphoma: the importance of antibody-specificity in determining successful treatment of established disease Blood 1999 94: 233–243

    CAS  PubMed  Google Scholar 

  89. Kaminski MS, Gribbin T, Estes J, Ross CW, Regan D, Zasadny K, Tamminen J, Kison P, Tuck M, Fisher S, Petry N, Wahl RL . I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions Proc Am Soc Clin Oncol 1998 17: 2a

    Google Scholar 

  90. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Thomas ED, Bernstein ID . Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas Lancet 1995 346: 336–340

    CAS  PubMed  Google Scholar 

  91. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL . Iodine-131-anti-B-1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 1996 14: 1974–1981

    CAS  PubMed  Google Scholar 

  92. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS . Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 2000 18: 1316–1323

    CAS  PubMed  Google Scholar 

  93. Kaminski MS, Estes J, Tuck M, Mann J, Fisher S, Kison P, Regan D, Stagg R, Kroll S, Magnuson DE, Wahl RL . Iodine I-131 tositumomab therapy for previously untreated follicular lymphoma Proc Am Soc Clin Oncol 2000 19: 5a (Abstr. 11)

    Google Scholar 

  94. Horning SJ, Lucas JB, Younes A, Podoloff D, Jain V, Kroll S, Stagg R, Nadeau K, Tidmarsh G . Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: results of a multi-center phase II study Blood 2000 96 (Suppl. 1): 508a (Abstr. 2184)

    Google Scholar 

  95. Kaminski M, Estes J, Regan D, Tuck M, Zasadny K, Kison P, Kroll S, Stagg R, Wahl RL . Retreatment with tositumomab and iodine I-131 tositumomab (BexxarTM) for patients with low-grade or transformed low-grade non-hodgkin lymphoma (NHL) Proc Am Soc Clin Oncol 2001 20: 285a (Abstr. 1139)

    Google Scholar 

  96. Bennett JM, Zelenetz AD, Press OW, Vose JM, Radford JA, Knox SJ, Wilkinson M, Schwartz RS, Kaminski MS, Capizzi R . Incidence of myelodysplastic syndromes (tMDS) and acute myeloid leukemia (tAML) in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) treated with Bexxarω Blood 2001 98 (Suppl. 1): 335a (Abstr 1416)

    Google Scholar 

  97. Press OW, Unger JM, Braziel RM, Maloney DG, LeBlanc ML, Grogan TM, Miller TP, Fisher RI . A phase II trial of CHOP followed by Bexxar[TM] (tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911) Blood 2001 98 (Suppl. 1): 843a (Abstr. 3504)

    Google Scholar 

  98. Vose JM, Bierman PJ, Lynch JC, Gobar L, Augustine S, Dukat V, Bociek G, Tidmarsh G, Armitage JO . Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): synergistic results with no added toxicity Proc Am Soc Clin Oncol 2001 20: 6a (Abstr. 19)

    Google Scholar 

  99. Gopal AK, Petersdorf S, Maloney D, Eary J, Wood B, Rajendran J, Bush S, Durack L, Gooley T, Martin P, Matthews D, Appelbaum F, Bernstein I, Press OW . High-dose I-131-anti CD-20 antibody therapy (tositumomab), etoposide, cyclophosphamide and autologous stem cell transplantation for patients with relapsed or refractory mantle cell lymphoma Proc Am Soc Clin Oncol 2001 20: 280a (Abstr. 1118)

    Google Scholar 

  100. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ . Phase I/II trail of IDEC-Y2B2 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma J Clin Oncol 1999 17: 3793–3803

    CAS  PubMed  Google Scholar 

  101. Witzig TE, White CA, Gordon LI, Murray JL, Wiseman GA, Emmanouilides C, Czuczman MS, Shen D, Multani P, Grillo-Lopez AJ . Final results of a randomized controlled study of the Zevalinω radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL Blood 2000 96 (Suppl. 1): 831a (Abstr. 3591)

    Google Scholar 

  102. Flinn IW, Witzig TE, White CA, Gordon L, Emmanouilides C, Cripe LD, Saleh M, Czuczman MS, Spies S, Silverman DH, Burt RW . The Zevalin radioimmunotherapy (RIT) regimen is active in heavily pretreated, bulky, Rituximab refractory NHL Proc Am Soc Clin Oncol 2001 20: 286a (Abstr. 1141)

    Google Scholar 

  103. Gordon L, Witzig T, Schilder R, Bartlett N, Emmanouilides C, Multani P, White C . High-dose therapy can be safely and successfully administered after Zevalin treatment Proc Am Soc Clin Oncol 2001 20: 232b (Abstr. 2681)

    Google Scholar 

  104. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS . Zevalin[TM] radioimmunotherapy can be safely administered to patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) Blood 2001 98 (Suppl. 1): 606a (Abstr. 2539)

    Google Scholar 

  105. Emmanouilides C, Silverman D, Leigh B, Territo M . Successful treatment of Waldenstrom's Macroglubinemia with Zevalin-based therapy: a case report Blood 2001 98 (Suppl. 1): 241b (Abstr. 4691)

    Google Scholar 

  106. Winter JN, Inwards D, Erwin W, Wiseman G, Rademaker A, Patton D, Williams S, Tallman M, Mehta J, Singhal S, Micallef I, Spies S, Multani P, Zimmer M, White C, Gordon LI . Phase I Trial Combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL Blood 2001 98 (Suppl. 1): 677a (Abstr. 2835)

    Google Scholar 

  107. Kosmas C, Snook DE, Gooden CS, Courtenay-Luck NS, McCall MJ, Meares C, Epenetos AA . Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy Cancer Res 1992 52: 904–911

    CAS  PubMed  Google Scholar 

  108. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA . Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy J Nucl Med 1995 36: 746–753

    CAS  PubMed  Google Scholar 

  109. Wiseman G, White C, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-Lopez AJ . Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory NHL Eur J Nucl Med 2000 27: 766–777

    CAS  PubMed  Google Scholar 

  110. Grossbard M, Press OW, Appelbaum FR, Bernstein ID, Nadler LM . Monoclonal antibody-based therapies of leukemia and lymphoma Blood 1992 80: 863–878

    CAS  PubMed  Google Scholar 

  111. Glennie MJ, Johnson PWM . Clinical trials of monoclonal antibodies Immunol Today 2000 21: 403–410

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, 2nd Division of Medical Oncology, ‘Metaxa’ Cancer Hospital, Piraeus, Greece

    C Kosmas

  2. Department of Hematology, G Papanicolaou General Hospital, Thessaloniki, Greece

    K Stamatopoulos & N Stavroyianni

  3. Department of Pathophysiology, Oncology Unit, Athens University School of Medicine, Laikon General Hospital, Athens, Greece

    N Tsavaris

  4. Hemopathology Department, Evangelismos Hospital, Athens, Greece

    T Papadaki

Authors
  1. C Kosmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Stamatopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Stavroyianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Tsavaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Papadaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kosmas, C., Stamatopoulos, K., Stavroyianni, N. et al. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 16, 2004–2015 (2002). https://doi.org/10.1038/sj.leu.2402639

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402639

Keywords

This article is cited by

Search

Advanced search

Quick links